Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GoodRx Holdings, Inc.GDRX · Entity 4838 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GoodRx Holdings, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 343,810 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 73,434 · Balance 343,810 F1: Reflects restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Class A common stock. The restricted stock units vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 and (ii) the date of the 2027 Annual Meeting of Stockholders, subject to Reporting Person's continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy TB 2024-2 GRAT | 543,377 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 543,377 F2: Share held directly by TB 2024 -2 GRAT, a grantor retained annuity trust (the "TB 2024-2 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the TB 2024-2 GRAT. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy TB 2025 GRAT | 2,089,343 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,089,343 F3: Share held directly by TB 2025 GRAT, a grantor retained annuity trust (the "TB 2025 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the TB 2025 GRAT. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Spouse | 1 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1 |
| Class A Common StockSEC Table I · non-derivative | IndirectBy JB 2024-2 GRAT | 543,377 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 543,377 F4: Share held directly by JB 2024-2 GRAT, a grantor retained annuity trust (the "JB 2024-2 GRAT"). Jana Bezdek, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the TB 2024-2 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the TB 2024-2 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy JB 2025 GRAT | 2,089,343 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,089,343 F5: Share held directly by JB 2025 GRAT, a grantor retained annuity trust (the " JB 2025 GRAT"). Jana Bezdek, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the JB 2025 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the JB 2025 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Class A common stock. The restricted stock units vest in full on the earlier of (i) the one-year anniversary of June 16, 2026 and (ii) the date of the 2027 Annual Meeting of Stockholders, subject to Reporting Person's continued service through the applicable vesting date.
F2: Share held directly by TB 2024 -2 GRAT, a grantor retained annuity trust (the "TB 2024-2 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the TB 2024-2 GRAT.
F3: Share held directly by TB 2025 GRAT, a grantor retained annuity trust (the "TB 2025 GRAT"). The Reporting Person serves as the sole trustee and sole annuitant of the TB 2025 GRAT.
F4: Share held directly by JB 2024-2 GRAT, a grantor retained annuity trust (the "JB 2024-2 GRAT"). Jana Bezdek, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the TB 2024-2 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the TB 2024-2 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares.
F5: Share held directly by JB 2025 GRAT, a grantor retained annuity trust (the " JB 2025 GRAT"). Jana Bezdek, the Reporting Person's spouse, serves as the sole trustee and sole annuitant of the JB 2025 GRAT. The Reporting Person has no pecuniary interest in or voting or investment control over the shares of Class A Common Stock held by the JB 2025 GRAT and disclaims beneficial ownership of such shares. This filing is not an admission or acknowledgment that the Reporting Person is the beneficial owner of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008976 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,594 Underlying: Class A Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F2 · derivative.exercise_date: The restricted stock unit vests in 16 equal quarterly installments commencing on September 1, 2020. F2 · derivative.expiration_date: The restricted stock unit vests in 16 equal quarterly installments commencing on September 1, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008976 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,592,323 Underlying: Class B Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock unit vests in 16 equal quarterly installments commencing on September 1, 2020. F2 · derivative.expiration_date: The restricted stock unit vests in 16 equal quarterly installments commencing on September 1, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 131,066 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008976 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 00:14 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 365,661 | $42.45 | $15,522,309.45 |
DisclosureSEC source: 0000899243-20-034539 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 365,661 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 00:14 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 365,661 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034539 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,661 Underlying: Class A Common Stock · 365,661 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 00:14 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Units · Derivative | 365,661 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034539 · doc4.xml · derivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,845,361 Underlying: Class B Common Stock · 365,661 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock units vested upon the achievement of performance goals. Settlement of the restricted stock units is delayed until the third anniversary of the applicable vesting date, however the Issuer may accelerate the settlement of a number of RSUs sufficient to satisfy any FICA tax withholding obligations. The December 16, 2020 transaction reflects acceleration of the settlement of RSUs to satisfy FICA tax withholding obligations. F2 · derivative.expiration_date: The restricted stock units vested upon the achievement of performance goals. Settlement of the restricted stock units is delayed until the third anniversary of the applicable vesting date, however the Issuer may accelerate the settlement of a number of RSUs sufficient to satisfy any FICA tax withholding obligations. The December 16, 2020 transaction reflects acceleration of the settlement of RSUs to satisfy FICA tax withholding obligations. Read SEC document |
| December 07, 2020 Filed Dec 7, 2020 22:10 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass B Common Stock · Derivative | 130,968 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032873 · doc4.xml · derivative · entry 5 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 130,968 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 07, 2020 Filed Dec 7, 2020 22:10 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | ConversionClass A Common Stock | 130,968 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032873 · doc4.xml · nonDerivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2020 Filed Dec 7, 2020 22:10 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Tax withholdingClass B Common Stock · Derivative | 125,626 | $36.81 | $4,624,293.06 |
DisclosureSEC source: 0000899243-20-032873 · doc4.xml · derivative · entry 4 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,968 Underlying: Class A Common Stock · 125,626 shares Expires not disclosed F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 01, 2020 Filed Dec 7, 2020 22:10 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionClass B Common Stock · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032873 · doc4.xml · derivative · entry 3 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,594 Underlying: Class A Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.exercise_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. F3 · derivative.expiration_date: Each share of Class B common stock is convertible at any time at the option of the holder into one share of the Issuer's Class A common stock or upon the earliest to occur of (1) the first date on which the aggregate number of outstanding shares of Class B common stock ceases to represent at least 10% of the then-outstanding shares of common stock, (2) the transfer of such share of Class B common stock, other than certain permitted transfers, or (3) September 25, 2027. Read SEC document |
| December 01, 2020 Filed Dec 7, 2020 22:10 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | Exercise / conversionRestricted Stock Unit · Derivative | 256,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032873 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,848,917 Underlying: Class B Common Stock · 256,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock unit vests in 16 equal quarterly installments commencing on September 1, 2020. F2 · derivative.expiration_date: The restricted stock unit vests in 16 equal quarterly installments commencing on September 1, 2020. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 20:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | GrantRestricted Stock Unit · Derivative | 8,211,022 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026463 · doc4.xml · derivative · entry 2 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,211,022 Underlying: Class B Common Stock · 8,211,022 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F3 · derivative.exercise_date: The restricted stock unit vests upon the achievement of performance goals for the twenty-day moving average of the Issuer's Class A common stock price, with such goals ranging from $6.07 per share to $51.28 per share. F3 · derivative.expiration_date: The restricted stock unit vests upon the achievement of performance goals for the twenty-day moving average of the Issuer's Class A common stock price, with such goals ranging from $6.07 per share to $51.28 per share. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 20:30 UTC | GoodRx Holdings, Inc. GDRX · Entity 4838 | GrantRestricted Stock Unit · Derivative | 4,105,511 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026463 · doc4.xml · derivative · entry 1 Bezdek Trevor · CIK 0001822104 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,105,511 Underlying: Class B Common Stock · 4,105,511 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class B common stock. F2 · derivative.exercise_date: The restricted stock unit vests in 16 equal quarterly installments commencing on September 1, 2020. F2 · derivative.expiration_date: The restricted stock unit vests in 16 equal quarterly installments commencing on September 1, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.